Overview:


DOWNLOAD THE 2010 CONFERENCE PROGRAMME

Click here to download a pdf version of the event brochure from the 2010 event including full programme details.

  


The global life sciences industry faces an unprecedented array of challenges. Adding to the already heady mix of patent expirations and falling R&D productivity comes the challenge of new healthcare reforms in the US, and the advent of evidence based medicine as a global phenomenon with the potential to transform the fortunes and business models of the industry. Faced with these new realities, how can life science companies prepare?

Chaired by Andrew Jack, Pharmaceuticals Correspondent of the Financial Times, the FT Global Pharmaceutical and Biotechnology Conference, now in its 27th successful year, brings together leading industry executives, government decision makers, investors, analysts and other specialist providers to discuss the latest  industry developments, and provide insights that will help you identify, anticipate and meet tomorrow's challenges head on .


         CONFIRMED SPEAKERS INCLUDE

  

 
Joseph Jimenez, Chief Executive Officer, Novartis
David Brennan, Chief Executive Officer, AstraZeneca
Eddie Gray, President, Pharmaceuticals Europe, GlaxoSmithKline
Dr Erich Hunziker, Chief Financial and IT Officer, Roche
Dr Roch Doliveux, Chief Executive Officer, UCB
Jérôme Contamine, EVP, Chief Financial Officer, Sanofi-Aventis
Dr Jan Lundberg, EVP, Science and Technology and President, Lilly Research Laboratories
Jeffrey Berkowitz, SVP, Global Market Access, Merck & Co
Timothy C Tyson, Chairman and CEO, Aptuit, Inc
Sir Andrew Dillon, Chief Executive, National Institute for Health and Clinical Excellence (NICE)
Ken Jones, Chief Operating Officer, Astellas Pharma Europe Ltd
Carolyn M Clancy MD, Director, Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services
Gerry Migliaccio, SVP, Network Performance, Pfizer Global Manufacturing, Pfizer Inc
Rolf Hoffmann, Senior Vice President, Amgen International

       


Topics for discussion include:

  • US healthcare reform: what will be the implications for innovation in the US and internationally?
  • Maximising returns in R&D: Has the industry become too dependent on "externalisation"? Do recent biotech failures give cause for caution?
  • Pricing for value: what are the implications of a new era of evidence based medicine for pricing, R&D and commercial strategies?
  • The CFO agenda: From financing R&D, to making M&A pay, what are the strategies the industry's CFOs are employing to position their companies for growth?
  • Global supply chain: What are the emerging risks, and what are the strategies for managing the increasing complex supply chains for today's life science companies? How can the value of the supply chain be optimised?
  • International healthcare markets: To what extent are healthcare markets globally converging? As comparative effectiveness regimes and evidence based medicine become the norm, what can the industry do to ensure that decisions on value and health outcomes are fair and informed?